Cookies help us improve your experience. We use cookies to improve website functionality and performance throughout upharma-c.com. Click "accept all cookies” to continue browsing the site with its full range of features enabled.

Kazakhstan Pharmaceutical Country Report 2021 1HY

UPharma Consulting has developed and released a new report dedicated to the pharmaceutical market of Kazakhstan—"Kazakhstan Pharmaceutical Country Report 2021/1HY". The publication is devoted to the current status and latest developments in the pharmaceutical market trends, sales perspectives, market access process, current regulatory environment, healthcare system and expenditures, epidemiology, and country's demography. The Report is available for purchase either through the site or by requesting an invoice by the link.

Report about


Summary

We're happy to announce that our latest report "Kazakhstan Pharmaceutical Country Report 2021/1HY" publications—a business-style professional publication that describes and depicts the country, its pharmaceutical market infrastructure and trends, retail and hospital sales, healthcare system, epidemiology, and demographics—is available now. The Report explores the current dynamics in the Kazakhstani pharmaceutical market, its local pharma manufacturing industry, includes an overview of recent trends and sales numbers, a review of regulatory documents and detailed schemes of all market access process existing in the country.

Purchase report


Concept

We developed this report intending to show a picture of the current state of the pharmaceutical market in Kazakhstan, stages of market access, the Kazakhstan healthcare system, and the country's epidemiological situation as concisely and clearly as possible.

The structure, navigation, and content of the report are designed in such a way as to convey to users the most important in the most convenient format with convenient navigation and a list of graphs, tables, figure schemes.

Contents & Structure

The Report consists of four main sections:

  1. Country Summary
  2. Pharmaceutical Market Trends
  3. Market Access Roadmap
  4. Healthcare & Epidemiology


1. Country Summary

The country introductory section for 4-5 pages describing actual macroeconomic indicators and current trends in the social-economic development of Kazakhstan for the period of the Report.

2. Pharmaceutical Market Trends

One of the core sections of the Report is dedicated to the description of the current state of the Kazakhstan pharmaceutical market, its stakeholders, ongoing trends, dynamics, and sales patterns for the period of 2013-2021 1HY. The forecast of the Belarussian pharmaceutical market is shown for the 2022-2024 period. The section is given in tables, figures, summaries, and schemes.

  • Supply chain stakeholders
  • Supply chain scheme and flows
  • Pharmaceutical market dynamics by channels
  • Retail channel sales dynamics in 2013-2021 1HY
  • Hospital channel sales dynamics in 2013-2021 1HY
  • Outpatient reimbursement channel sales dynamics in 2013-2021 1HY
  • Average prices by segments
  • Retail and hospital channels sales in 2013-2021 1HY
  • Pharmaceutical retail infrastructure
  • Export and import of pharmaceuticals in Kazakhstan
  • Locally produced pharmaceutical products
  • Forecast of the pharmaceutical market sales in Kazakhstan for 2022-2024
  • Top-15 pharmaceutical companies in Kazakhstan
  • Top-15 pharmaceutical products in Kazakhstan
  • Marketing regulation environment

3. Market Access Roadmap

The second core section of the Report was developed to visualize the picture of all processes required for companies to bring their products to the country: from marketing authorization and pricing regulation to public purchases and national formulary ecosystems. The section "Pharmaceutical Market Access Roadmap" in Kazakhstan has the following sub-sections:

  • General regulatory environment.
  • Latest changes in all processes concerning market access in Kazakhstan.
  • Marketing authorization: Kazakhstan offers three options of marketing authorization for pharmaceutical products.
  • Early Access scheme in Kazakhstan.
  • Pricing regulation: formation and listing, mark-ups and their regulation.
  • Scheme of pricing mechanisms for pharmaceuticals in Kazakhstan.
  • Public procurement of medicines in Kazakhstan.
  • Essential Medicines List.
  • Pricing & Reimbursement of drugs in Kazakhstan.
  • Public procurement process.
  • HTA ecosystem in Kazakhstan.
  • Stakeholders of the market access process.
4. Healthcare System & Epidemiology

The fourth important section is dedicated to understanding the existing healthcare system, its infrastructure, workforce trends in Kazakhstan, together with the country's epidemiology situation, demographic trends, and state expenditures on healthcare:

  • Healthcare system spending in 2013-2021.
  • Healthcare budget by source in 2015-2021—Republican and Local.
  • Population and other key demographic indicators.
  • Healthcare infrastructure by regions for the period of 2016-2020.
  • Population morbidity in Kazakhstan in 2016-2019.
  • Main causes of death in Kazakhstan by ICD-10.
  • COVID-19 implications on country's economy healthcare systems, pharmaceutical market, and civil sector.

Technical Details

The report is delivered in the following format:

  • language: ENG
  • files: .pdf, .pptx (editable), .xlsx (all data and graphs)
  • number of pages: 57
  • number of tables: 27
  • number of schemes and figures: 43
  • size: A4 (album orientation)

Purchase report

List of Tables used in the Report:

The report is delivered in the following format:

  • 1. Socio-Economic Indicators in Kazakhstan: 1994 vs. 2020
  • 2. Main Macroeconomic Indicators of Kazakhstan in 2013-2021
  • 3. Kazakhstan in International Ratings 2013-2021
  • 4. Pharmaceutical Market Stakeholders Throughout the Supply Chain
  • 5. Kazakh Pharmaceutical Market by Channels in 2013-2021 (1-HY), USD mln
  • 6. Number of POS by TOP-10 Pharmacy Chains in Kazakhstan
  • 7. Top-15 Products in the Total Pharmaceutical Market of Kazakhstan, Values
  • 8. Top-15 Companies in the Total Pharmaceutical Market of Kazakhstan, Values
  • 9. Sales of Local & Foreign Products in the Retail Channel in Volumes in 2013-2020
  • 10. PESTL-Impact Analysis of the Kazakh Pharmaceutical Market as of 2021
  • 11. SWOT Analysis of the Kazakh Pharmaceutical Market
  • 12. COVID-19 Implications for the Kazakh Economy, Healthcare, Pharma, and Civic Sectors
  • 13. Authorities Responsible for Certain Policies and State Agencies Involved in the Market Access of Pharmaceuticals in Kazakhstan
  • 14. Authorities and State Agencies Involved in the Market Access of Pharmaceuticals in Kazakhstan (detailed information)
  • 15. Key Changes on the Road-to-Market Pathway in Kazakhstan in 2021
  • 16. Marketing Authorization Procedure Available Options
  • 17. The Size of the Marginal Mark-Ups for Trading Names Covered by Benefits Packages
  • 18. The Size of the Marginal Mark-Ups for Medicines Procured by Pharmacy Under the Benefits Packages
  • 19. Total State Budget and Budget on the Healthcare in Kazakhstan in 2013-2021 (e)
  • 20. Annual Healthcare Budget of Kazakhstan in % to GDP in 2013-2021 (e)
  • 21. Healthcare Infrastructure of Kazakhstan by the jurisdiction in 2013-2020
  • 22. Number of Hospitals under the MOH by types (2020)
  • 23. Number of physicians by main specializations in Kazakhstan, persons (2018-2020)
  • 24. Morbidity (incidence and prevalence) by disease groups in 2019-2020
  • 25. Population Incidence of Malignant Neoplasms by Individual Localizations and Reveal Stages (2018-2020)
  • 26. Morbidity (incidence and prevalence) by disease groups in 2019-2020
  • 27. Key Demographic Indicators, 2013-2020
Purchase report

List of Figures and Schemes used in the Report:

The report is delivered in the following format:

  • 1. GDP of Kazakhstan in 2013-2021 (e)
  • 2. Currency Exchange Rates of the Kazakhstani Tenge (KZT) vs USD and EUR in 2013-2022 (f)
  • 3. Schematic Visualization of the Supply Chain Scheme on the Pharmaceutical Market in Kazakhstan
  • 4. Shares of Channels of the Kazakh Pharmaceutical Market in 2013-2021 (1-HY)
  • 5. Shares of Rx & OTC Products in the Total Pharmaceutical Market of Kazakhstan
  • 6. Weighted Average Cost of a Pack per Sales Channel
  • 7. Total Sales in the Kazakh Pharmaceutical Market by Channels in Values During 2013-2021 (e)
  • 8. Total Sales in the Kazakh Pharmaceutical Market by Channels in Volumes During 2013-2021 (e)
  • 9. Retail Channel Sales Dynamics in Values in 2013-2021 (e) 
  • 10. Retail Channel Sales Dynamics in Volumes in 2013-2021 (e) 
  • 11. Hospital Channel Sales Dynamics in Values in 2013-2021 (e) 
  • 12. Hospital Channel Sales Dynamics in Volumes in 2013-2021 (e) 
  • 13. Outpatient Reimbursement Value Dynamics in 2013-2021 (e) 
  • 14. Outpatient Reimbursement Value Dynamics in 2013-2021 (e)
  • 15. Dynamics of the Total Number of POS in Kazakhstan in 2013-2020
  • 16. Retail Sales Turnover per POS in 2013-2021 (e)
  • 17. Number of Pharmacies by Regions of Kazakhstan
  • 18. Sales in the Retail Channel by Categories of Goods
  • 19. Top-15 Products in the Total Pharmaceutical Market of Kazakhstan, Values
  • 20. Top-15 Companies in the Total Pharmaceutical Market of Kazakhstan, Values
  • 21. Value of Locally Produced Pharmaceutical Products in Kazakhstan
  • 22. Total Value of Exported Pharmaceutical Products from Kazakhstan in 2013-2021 1-HY
  • 23. Total Value of Imported Pharmaceutical Products to Kazakhstan
  • 24. Balance of Foreign Trade of Pharmaceutical Products in Kazakhstan
  • 25. Total Pharma Market Sales Forecast, VALUES (Retail + Hospital + Outpatient Reimbursement)
  • 26. Total Pharma Market Sales Forecast, VOLUMES (Retail + Hospital + Outpatient Reimbursement)
  • 27. Scheme 1: National Marketing Authorization Procedure Harmonized with the EEU Requirements
  • 28. Scheme 2: Accelerated Marketing Authorization Procedure
  • 29. Scheme 3: Marketing Authorization Procedure in The Reference Country in Eurasian Economic Union Framework (Mutual Recognition Procedure)
  • 30. Decision-Making Procedure to Provide Medical Care for the Vital Indications of a Specific Patient or Group of Patients 
  • 31. Implemented Public Policies to Control Pharmaceutical Spending in Kazakhstan
  • 32. A Scheme of Price Regulation for Products Listed in the NMF
  • 33. The Price Formation Procedure Applied For Drugs Procured by SK-Pharmacy Under the Benefits Package
  • 34. Out-Patient Reimbursement Program Operation Scheme in KAZ
  • 35. Types of Out-Patient Reimbursement Program Scheme in Kazakhstan
  • 36. Public Purchases at an Outpatient and Inpatient Levels in Kazakhstan
  • 37. Public Purchases of Medicines and Medical Devices From International Organizations Established by the United Nations
  • 38. Public Purchases of Pharmaceuticals that Do Not Have an Authorized Analogue Within INN in KAZ
  • 39. Scheme of the National Formulary System in Kazakhstan
  • 40. Scheme of the National Medicines Formulary Inclusion Process in Kazakhstan
  • 41. Scheme of the HTA Procedure in Kazakhstan
  • 42. Annual Healthcare Budget of Kazakhstan in % to GDP (2014-2020)
  • 43. Medical Care Provision System in Kazakhstan
Purchase report

Download
our E-Brochure